Celldex Therapeutics Inc. (NASDAQ:CLDX) has a beta value of 1.52 and has seen 1.01 million shares traded in the last trading session. The company, currently valued at $2.61B, closed the last trade at $40.49 per share which meant it lost -$0.47 on the day or -1.15% during that session. The CLDX stock price is -31.34% off its 52-week high price of $53.18 and 45.39% above the 52-week low of $22.11. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.28 million shares traded. The 3-month trading volume is 932.24K shares.
Celldex Therapeutics Inc. (NASDAQ:CLDX) trade information
Sporting -1.15% in the red in last session, the stock has traded in the red over the last five days, when the CLDX stock price touched $40.49 or saw a rise of 14.76%. Year-to-date, Celldex Therapeutics Inc. shares have moved 2.09%, while the 5-day performance has seen it change -12.07%. Over the past 30 days, the shares of Celldex Therapeutics Inc. (NASDAQ:CLDX) have changed 5.86%. Short interest in the company has seen 6.41 million shares shorted with days to cover at 6.56.
Celldex Therapeutics Inc. (CLDX) estimates and forecasts
Figures show that Celldex Therapeutics Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained 50.46% over the past 6 months, with this year growth rate of -10.15%, compared to 12.40% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2024 fiscal year revenue. Growth estimates for the current quarter are -17.70% and -15.40% for the next quarter. Revenue growth from the last financial year stood is estimated to be -54.20%.
4 analysts offering their estimates for the company have set an average revenue estimate of $920k for the current quarter. 4 have an estimated revenue figure of $920k for the next quarter concluding in Jun 2024. Year-ago sales stood $967k and $268k respectively for this quarter and the next, and analysts expect sales will shrink by -4.90% for the current quarter and 243.30% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 27.41% over the past 5 years.
CLDX Dividends
Celldex Therapeutics Inc. is expected to release its next earnings report between May 02 and May 06 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Celldex Therapeutics Inc. (NASDAQ:CLDX)’s Major holders
Insiders own 0.35% of the company shares, while shares held by institutions stand at 96.66% with a share float percentage of 97.00%. Investors are also buoyed by the number of investors in a company, with Celldex Therapeutics Inc. having a total of 239 institutions that hold shares in the company. The top two institutional holders are FMR, LLC with over 7.05 million shares worth more than $285.47 million. As of Dec 30, 2023, FMR, LLC held 12.61% of shares outstanding.
The other major institutional holder is Wellington Management Group, LLP, with the holding of over 6.48 million shares as of Dec 30, 2023. The firm’s total holdings are worth over $262.24 million and represent 11.59% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Specialized-Health Care Fund and Mutual Fund Ser Tr-Eventide Gilead Fund. As of Oct 30, 2023, the former fund manager holds about 3.97% shares in the company for having 2.22 million shares of worth $89.87 million while later fund manager owns 1.82 million shares of worth $73.55 million as of Dec 30, 2023, which makes it owner of about 3.25% of company’s outstanding stock.
